Welcome to Monogram Biosciences

Home Page - Slider

HCV Specialty Diagnostic Testing
Oncology Receptor Testing
Pharma Collaborations
HIV Resistance Testing
HCV Specialty Diagnostic Testing
HCV Specialty Diagnostic Testing
Be confident in your treatment options.

Monogram has applied its virology expertise to hepatitis C. We offer a range of assays to assist with optimizing the treatment of patients with HCV.

Oncology Receptor Testing
Oncology Receptor Testing
Quantify cell-surface receptors.

The HERmark® Breast Cancer Assay is the industry’s first fully quantitative HER2 protein test based on Monogram’s proprietary VeraTag® protein quantification platform.

Pharma Collaborations
Pharma Collaborations
Specialty diagnostics for drug development.

Monogram provides biopharmaceutical partners with clinical, scientific, and logistical support for drug development projects in HIV, HCV, and oncology.

HIV Resistance Testing
HIV Resistance Testing
The right drug at the right time.

Monogram is a world leader in HIV drug resistance assays and viral tropism assays to aid in patient management.

A Decade of HIV Drug Resistance in the US

HERmark® Predicts Benefit from Dual HER2 Blockade in NeoALTTO
HER2

Pharma Collaborations

Monogram Biosciences is a valued research partner committed to our biopharmaceutical partners and research collaborators

News

LabCorp announces new agreements with UnitedHealthcare and Aetna
Read more

MonogramBio Features

Mutational data to guide regimen switches in suppressed patients

Learn More

To assess NS5A drug susceptibility in patients with Hepatitis C

Learn More

Precise quantification of patient HER2 expression

Learn More